US equities
|
MU
$1,037.21
▼-4.67%
NVDA
$230.38
▼-2.99%
SNDK
$1,601.34
▼-5.38%
AMD
$616.83
▼-4.49%
INTC
$106.02
▼-6.28%
SPCX
$160.93
▼-3.98%
PLTR
$196.07
▲+1.00%
META
$714.47
▼-0.95%
MU
$1,037.21
▼-4.67%
NVDA
$230.38
▼-2.99%
SNDK
$1,601.34
▼-5.38%
AMD
$616.83
▼-4.49%
INTC
$106.02
▼-6.28%
SPCX
$160.93
▼-3.98%
PLTR
$196.07
▲+1.00%
META
$714.47
▼-0.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Amphastar Pharmaceuticals, Inc. - Common Stock
(NQ:
AMPH
)
26.02
+0.48 (+1.88%)
Delayed Quote
Updated: 1:24 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
1 Safe-and-Steady Stock to Research Further and 2 Facing Challenges
Today 0:40 EDT
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Fi...
Via
StockStory
3 Stocks Under $50 We Think Twice About
October 01, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
Topics
Supply Chain
3 Reasons to Avoid AMPH and 1 Stock to Buy Instead
September 24, 2026
Over the past six months, Amphastar Pharmaceuticals has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $24.97, representing...
Via
StockStory
Topics
Stocks
Supply Chain
3 Russell 2000 Stocks We Find Risky
September 21, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via
StockStory
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate
↗
August 15, 2026
Via
Chartmill
Amphastar Pharmaceuticals (NASDAQ:AMPH) Beats Q2 Earnings Estimates, Shares Rise After Hours
↗
August 06, 2026
Via
Chartmill
Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal
↗
July 18, 2026
Via
Chartmill
3 Small-Cap Stocks with Warning Signs
September 18, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via
StockStory
Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group
September 16, 2026
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals e...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Healthcare Stocks We Keep Off Our Radar
September 01, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
Via
StockStory
1 Cash-Producing Stock on Our Buy List and 2 We Question
August 27, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Via
StockStory
Amphastar (AMPH) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
New product launches drove 5% revenue growth and margin expansion.
Via
The Motley Fool
Topics
Earnings
The Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call
August 13, 2026
Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portf...
Via
StockStory
Topics
Earnings
AMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive Results
August 07, 2026
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 5.4% year on y...
Via
StockStory
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
↗
August 06, 2026
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is...
Via
MarketBeat
Topics
Earnings
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026
August 06, 2026
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 5.4% year o...
Via
StockStory
What To Expect From Amphastar Pharmaceuticals’s (AMPH) Q2 Earnings
August 04, 2026
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting results this Thursday after market hours. Here’s what to look for. Amphastar ...
Via
StockStory
Topics
Artificial Intelligence
1 Value Stock to Own for Decades and 2 Facing Challenges
August 03, 2026
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
Via
StockStory
1 Profitable Stock with Impressive Fundamentals and 2 Facing Headwinds
July 28, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
3 Reasons AMPH is Risky and 1 Stock to Buy Instead
July 28, 2026
Amphastar Pharmaceuticals has gotten torched over the last six months - since January 2026, its stock price has dropped 27.6% to $18.92 per share. This was p...
Via
StockStory
Topics
Supply Chain
3 Stocks Under $50 We Keep Off Our Radar
July 22, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
Topics
Energy
1 of Wall Street’s Favorite Stocks to Research Further and 2 Facing Challenges
July 10, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via
StockStory
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
June 12, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Via
StockStory
Topics
Artificial Intelligence
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
↗
June 10, 2026
Amphastar Pharmaceuticals (NASDAQ:AMPH) is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice...
Via
MarketBeat
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
↗
June 04, 2026
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in...
Via
MarketBeat
3 Stocks Under $50 with Open Questions
May 26, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today
May 14, 2026
What Happened? Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 2.8% in the morning session after Wells Fargo downgraded the comp...
Via
StockStory
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
↗
May 14, 2026
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to...
Via
MarketBeat
The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings Call
May 14, 2026
Amphastar Pharmaceuticals’ first quarter was marked by flat revenue and a significant shortfall in non-GAAP profit compared to analyst expectations, promptin...
Via
StockStory
Topics
Earnings
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment
May 12, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
